Cocrystal Pharma, Inc.
COCP · XNASCIK 1412486fmd_1PF1J38015QCS3Q8NTVS1MVS9KManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Jun 30, 2026, 65 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 7 | 2 | – | – | – | – | – |
| Cost of revenue | – | – | – | – | – | – | – | – | – | – |
| Net interest income | – | (0) | (0) | (0) | – | – | – | – | – | – |
| Gross profit | – | – | – | – | – | – | – | – | – | – |
| Research and development | 102 | 6 | 5 | 4 | 6 | 9 | 12 | 15 | 13 | 5 |
| Selling, general and administrative | – | – | – | – | – | – | – | – | – | – |
| Total operating expenses | 106 | 8 | 63 | 55 | 12 | 14 | 39 | 19 | 18 | 9 |
| Operating income | (106) | (8) | (63) | (48) | (10) | (14) | (39) | (19) | (18) | (9) |
| Interest expense | – | – | 0 | 0 | 0 | 0 | 0 | (1) | (1) | (0) |
| Other non-operating income (expense) | 2 | 1 | 0 | 0 | (0) | 0 | (0) | 1 | 0 | 0 |
| Income before taxes | (104) | (7) | (63) | (48) | (10) | – | – | – | (19) | (9) |
| Income tax expense | (29) | (7) | (14) | – | – | – | – | – | – | – |
| Net income from continuing operations | (75) | (1) | (49) | – | – | – | – | – | – | – |
| Net income | (75) | (1) | (49) | (48) | (10) | (14) | (39) | (18) | (18) | (9) |
| Net income to common shareholders | – | (1) | (49) | (48) | – | – | – | – | – | – |